Roche Diagnostics Corp.'s Elecsys Anti-SARS-CoV-2 antibody test has been granted US Food and Drug Administration emergency use authorization and is now available in all markets accepting the CE mark.
The company said that based on a study of nearly 5,300 samples, the serology test, for immunoglobulin G (IgG) antibodies, has a specificity of 99.8%. The test also has a sensitivity of 100% some 14 days after infection has been confirmed by polymerase chain reaction (PCR) testing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?